Exact Sciences Corp. (NASDAQ: EXAS) announced performance data for a second-generation Cologuard (multi-target stool DNA) test showing overall sensitivity of 95.2% for colorectal cancer...
Parse Biosciences, a company providing researchers with single-cell sequencing solutions, today announced a partnership with Research Instruments Pte Ltd to provide Parse’s Evercode Whole...
A2 Biotherapeutics, Inc. ("A2 Bio") is a biotechnology company focused on the development of a first-in-class, logic-gated Tmod™ CAR T cell therapy platform to...
Regeneron Pharmaceuticals, Inc. and Sanofi announced positive pivotal results from a second Phase 3 trial, PRIME, evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo...
Regulated information – Inside information – UCB announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc.,...
